TABLE 3.
Association between age and receipt of adjuvant therapy amongst women with clinical T1N0, ER+, HER2− breast cancer, stratified by nodal status.
| NODE POSITIVE | ||||||||
| Age group | Chemotherapy N (%) | RD (95% CI)a | Radiation N (%) | RD (95% CI)a | Hormonal Therapy N (%) | RD (95% CI)a | Any Adjuvant N (%) | RD (95% CI)a |
| 18–29 | † | 0.19 (0.07, 0.31) | † | −0.05 (−0.17, 0.06) | † | 0.00 (−0.07, 0.07) | † | 0.01 (0.00, 0.01) |
| 30–39 | 252 (86) | 0.14 (0.10, 0.19) | 274 (93) | −0.01 (−0.04, 0.02) | 278 (95) | −0.02 (−0.05, 0.00) | † | 0.00 (−0.02, 0.01) |
| 40–49 | 1,769 (75) | 0.05 (0.03, 0.08) | 2197 (94) | −0.01 (−0.02, 0.00) | 2,282 (97) | 0.00 (0.00, 0.01) | 2,331 (99) | 0.00 (0.00, 0.00) |
| 50–59 | 3,358 (70) | REF | 4519 (95) | REF | 4,627 (97) | REF | 4,750 (99) | REF |
| 60–69 | 3,357 (60) | −0.09 (−0.11, −0.07) | 5238 (94) | −0.01 (−0.02, 0.00) | 5,422 (97) | 0.00 (−0.01, 0.01) | 5,553 (99) | 0.00 (−0.01, 0.00) |
| 70–79 | 1,359 (42) | −0.26 (−0.29, −0.24) | 2845 (88) | −0.06 (−0.07, −0.04) | 3,108 (97) | 0.00 (−0.01, 0.01) | 3,188 (99) | 0.00 (−0.01, 0.00) |
| 80–89 | 238 (27) | −0.41 (−0.44, −0.37) | 683 (78) | −0.16 (−0.19, −0.13) | 834 (95) | −0.02 (−0.04, 0.00) | 862 (98) | −0.02 (−0.03, −0.01) |
| ≥90 | † | −0.52 (−0.64, −0.39) | 28 (68) | −0.29 (−0.44, −0.13) | † | 0.01 (−0.04, 0.06) | † | 0.01 (0.00, 0.01) |
| NODE NEGATIVE | ||||||||
| Age group | Chemotherapy N (%) | RD (95% CI)a | Radiation N (%) | RD (95% CI)a | Hormonal Therapy N (%) | RD (95% CI)a | Any Adjuvant N (%) | RD (95% CI)a |
| 18–29 | 41 (55) | 0.27 (0.16, 0.39) | † | −0.03 (−0.10, 0.03) | † | 0.01 (−0.04, 0.05) | † | 0.00 (−0.03, 0.02) |
| 30–39 | 565 (50) | 0.22 (0.19, 0.25) | 1,052 (92) | −0.03 (−0.04, −0.01) | 1,068 (94) | −0.01 (−0.03, −0.00) | 1,121 (99) | 0.00 (−0.01, 0.00) |
| 40–49 | 3,799 (31) | 0.04 (0.03, 0.05) | 11,730 (95) | 0.00 (−0.01, 0.00) | 11,851 (96) | 0.01 (0.00, 0.01) | 12,218 (99) | 0.00 (0.00, 0.00) |
| 50–59 | 7,668 (27) | REF | 27,400 (95) | REF | 27,480 (96) | REF | 28,483 (99) | REF |
| 60–69 | 9,656 (22) | −0.04 (−0.05, −0.04) | 41,129 (93) | −0.01 (−0.01, −0.01) | 41,873 (95) | 0.00 (−0.01, 0.00) | 43,526 (99) | 0.00 (0.00, 0.00) |
| 70–79 | 5,402 (17) | −0.08 (−0.09, −0.07) | 23,280 (74) | −0.20 (−0.21, −0.19) | 29,159 (93) | −0.03 (−0.03, −0.02) | 30,499 (97) | −0.02 (−0.023, −0.02) |
| 80–89 | 1,208 (12) | −0.11 (−0.12, −0.09) | 4,388 (52) | −0.42 (−0.43, −0.41) | 7,337 (87) | −0.08 (−0.09, −0.07) | 7,812 (93) | −0.06 (−0.07, −0.05) |
| ≥90 | 47 (17) | −0.07 (−0.12, −0.02) | 61 (22) | −0.72 (−0.77, −0.67) | 207 (75) | −0.19 (−0.25, −0.14) | 230 (84) | −0.15 (−0.20, −0.11) |
a
Adjusted histology, year of diagnosis, race/ethnicity, Charlson Comorbidity Index, insurance type, residential urbanicity, median residential income, and residential education level
†
Cell value suppressed for patient number